HIV/AIDS: Global Response, Statistics & US Government Efforts (2024)

The global fight against HIV/AIDS, now in its fifth decade, remains a critical public health challenge. Approximately 40.8 million people are currently living with HIV, and since the epidemic’s beginning, tens of millions have died from AIDS-related causes. While significant progress has been made through concerted global efforts like the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, substantial hurdles remain in prevention, treatment, and care access, and, crucially, there is still no cure.

A History of Response and Recent Shifts

The HIV epidemic was first officially recognized in 1981, with the initial reporting of unusual pneumonia cases among young men in Los Angeles. The timeline of the epidemic has been marked by periods of fear, stigma, and scientific breakthroughs. Over the past two decades, major global initiatives have dramatically altered the course of the epidemic, reducing new infections and AIDS-related deaths. PEPFAR, launched in 2003, has been particularly impactful, directing over $130 billion toward prevention, care, and treatment. But, the landscape of U.S. Global health efforts has shifted in recent years, impacting the trajectory of these programs.

Understanding HIV and AIDS

HIV, or human immunodeficiency virus, attacks the body’s immune system, specifically targeting white blood cells called CD4 cells. As HIV weakens the immune system, the body becomes more vulnerable to opportunistic infections and certain cancers. If left untreated, HIV can progress to AIDS, or acquired immunodeficiency syndrome, the most advanced stage of infection. The World Health Organization (WHO) defines Advanced HIV Disease (AHD) as a CD4 cell count below 200 cells/mm3 or a specific stage 3 or 4 event. It’s significant to note that AIDS is now often seen in individuals who have stopped antiretroviral therapy (ART), rather than solely as a result of late diagnosis.

Global Prevalence and Impact

As of 2024, approximately 40.8 million people worldwide are living with HIV, an increase from 32 million in 2010. This rise is due to both continuing new infections and people living longer with the virus thanks to treatment advances. However, the global prevalence among adults has leveled off at 0.7%, though rates vary significantly among key populations, including men who have sex with men, sex workers, people who inject drugs, and transgender individuals. Sub-Saharan Africa remains the most heavily affected region, accounting for approximately two-thirds of all people living with HIV globally. Epidemiological data indicates that approximately 1.3 million new HIV infections occurred in 2024.

Vulnerable Populations and Disparities

While HIV can affect anyone, certain populations face a disproportionately higher risk. Women and girls represent over half of all people living with HIV worldwide, and HIV is a leading cause of death among women of reproductive age. This disparity is linked to gender inequalities, limited access to services, and increased vulnerability to sexual violence. Young people also face barriers to accessing HIV prevention and sexual and reproductive health services. Children, while representing a smaller proportion of those living with HIV (1.4 million in 2024), are less likely to receive treatment compared to adults, and new infections, though declining, remain a concern.

The Intertwined Epidemic of Tuberculosis

HIV and tuberculosis (TB) have a dangerous synergistic relationship. HIV weakens the immune system, making individuals more susceptible to TB infection, and TB accelerates the progression of HIV. TB is a leading cause of death for people living with HIV globally. However, integrated HIV/TB services have led to substantial declines in TB-related deaths among people with HIV since 2010.

Prevention and Treatment Strategies

A range of prevention strategies are available, including behavior change programs, condom use, HIV testing, and harm reduction efforts for people who inject drugs. Recent advancements include pre-exposure prophylaxis (PrEP), which has proven highly effective in preventing HIV infection in high-risk individuals. WHO guidelines now recommend long-acting injectable PrEP as a further option. Treatment involves combination antiretroviral therapy (ART), which suppresses the virus and allows people living with HIV to live long and healthy lives. Importantly, achieving viral suppression not only benefits the individual but also effectively eliminates the risk of sexual transmission – a concept known as “treatment as prevention” (TasP).

Global Goals and Funding

International efforts are guided by the Sustainable Development Goals (SDGs), with a target to end AIDS as a public health threat by 2030. UNAIDS has set interim “95-95-95” targets – 95% of people living with HIV knowing their status, 95% of those diagnosed on treatment, and 95% of those on treatment with suppressed viral loads – to be achieved by 2025. While progress has been made, achieving these targets requires sustained funding and commitment. In 2024, an estimated $18.7 billion was available for HIV efforts in low- and middle-income countries, with donor governments providing the largest share. However, UNAIDS estimates that at least $21.9 billion annually will be needed to reach the 2030 goal.

The Role of the U.S. And PEPFAR’s Future

The United States is the single largest donor to international HIV efforts, primarily through PEPFAR. Since its inception, PEPFAR has invested over $130 billion in prevention, care, and treatment programs. However, recent shifts in U.S. Foreign policy have led to changes within PEPFAR, including a focus on transitioning services to host country governments and potential funding reductions. The long-term impact of these changes on the global HIV response remains to be seen.

Looking ahead, continued investment in prevention, treatment, and research, coupled with a commitment to addressing the social and economic factors that drive the epidemic, will be crucial to achieving the goal of ending AIDS as a public health threat by 2030. Ongoing surveillance, adaptation of strategies based on evolving data, and a focus on equitable access to services will be essential to navigate the challenges that lie ahead.